| Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition N Jacque, AM Ronchetti, C Larrue, G Meunier, R Birsen, L Willems, ... Blood, The Journal of the American Society of Hematology 126 (11), 1346-1356, 2015 | 379 | 2015 |
| Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia P Sujobert, V Bardet, P Cornillet-Lefebvre, JS Hayflick, N Prie, F Verdier, ... Blood 106 (3), 1063-1066, 2005 | 350 | 2005 |
| Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid … J Tamburini, N Chapuis, V Bardet, S Park, P Sujobert, L Willems, N Ifrah, ... Blood, The Journal of the American Society of Hematology 111 (1), 379-382, 2008 | 321 | 2008 |
| CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphoma I Salaverria, C Royo, A Carvajal-Cuenca, G Clot, A Navarro, A Valera, ... Blood, The Journal of the American Society of Hematology 121 (8), 1394-1402, 2013 | 234 | 2013 |
| Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients S Georgin‐Lavialle, B Terrier, AF Guedon, M Heiblig, T Comont, E Lazaro, ... British Journal of Dermatology 186 (3), 564-574, 2022 | 232 | 2022 |
| A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts S Huet, B Tesson, JP Jais, AL Feldman, L Magnano, E Thomas, ... The lancet oncology 19 (4), 549-561, 2018 | 212 | 2018 |
| Therapeutic options in VEXAS syndrome: insights from a retrospective series E Bourbon, M Heiblig, M Gerfaud Valentin, T Barba, CA Durel, JC Lega, ... Blood, The Journal of the American Society of Hematology 137 (26), 3682-3684, 2021 | 204 | 2021 |
| The genetic basis of hepatosplenic T-cell lymphoma M McKinney, AB Moffitt, P Gaulard, M Travert, L De Leval, A Nicolae, ... Cancer discovery 7 (4), 369-379, 2017 | 197 | 2017 |
| Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma F Lemonnier, J Dupuis, P Sujobert, O Tournillhac, M Cheminant, ... Blood, The Journal of the American Society of Hematology 132 (21), 2305-2309, 2018 | 161 | 2018 |
| From genetics to the clinic: a translational perspective on follicular lymphoma S Huet, P Sujobert, G Salles Nature Reviews Cancer 18 (4), 224-239, 2018 | 134 | 2018 |
| High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells L Poulain, P Sujobert, F Zylbersztejn, S Barreau, L Stuani, M Lambert, ... Leukemia 31 (11), 2326-2335, 2017 | 130 | 2017 |
| Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center P Sesques, E Ferrant, V Safar, F Wallet, J Tordo, A Dhomps, L Karlin, ... American journal of hematology 95 (11), 1324-1333, 2020 | 120 | 2020 |
| Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study M Heiblig, MA Ferrada, MT Koster, T Barba, M Gerfaud-Valentin, ... Blood, The Journal of the American Society of Hematology 140 (8), 927-931, 2022 | 116 | 2022 |
| Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience A Diarra, N Duployez, E Fournier, C Preudhomme, V Coiteux, L Magro, ... Blood Advances 6 (3), 998-1003, 2022 | 114 | 2022 |
| Co-activation of AMPK and mTORC1 induces cytotoxicity in acute myeloid leukemia P Sujobert, L Poulain, E Paubelle, F Zylbersztejn, A Grenier, M Lambert, ... Cell reports 11 (9), 1446-1457, 2015 | 106 | 2015 |
| VEXAS syndrome in a woman T Barba, Y Jamilloux, CA Durel, E Bourbon, F Mestrallet, P Sujobert, A Hot Rheumatology 60 (11), e402-e403, 2021 | 89 | 2021 |
| Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia AS Green, TT Maciel, MA Hospital, C Yin, F Mazed, EC Townsend, ... Science advances 1 (8), e1500221, 2015 | 88 | 2015 |
| CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features B Bisig, A de Reyniès, C Bonnet, P Sujobert, DS Rickman, T Marafioti, ... haematologica 98 (8), 1250, 2013 | 82 | 2013 |
| Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma L Jallades, L Baseggio, P Sujobert, S Huet, K Chabane, E Callet-Bauchu, ... haematologica 102 (10), 1758, 2017 | 68 | 2017 |
| Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study D Luque Paz, J Riou, E Verger, B Cassinat, A Chauveau, JC Ianotto, ... Blood Advances 5 (5), 1442-1451, 2021 | 53 | 2021 |
Valerie BardetPU-PH, Université Versailles St Quentin-Université Paris Saclay, AP-HP, CEA UMR INSERM 1184在 aphp.fr 的电子邮件经过验证
